Eversept Partners
Latest statistics and disclosures from Eversept Partners's latest quarterly 13F-HR filing:
- Top 5 stock holdings are GSK, ENSG, DHR, Ascendis Pharma A S, Zogenix, and represent 31.70% of Eversept Partners's stock portfolio.
- Added to shares of these 10 stocks: Chemocentryx (+$20.30M), BCRX (+$14.66M), Pennant Group Inc (+$12.28M), Amarin Corp Plc option (+$11.59M), SNY (+$10.12M), MDCO (+$9.71M), Sarepta Therapeutics (+$9.68M), Spdr S&p 500 Etf Tr option (+$9.49M), Apellis Pharmaceuticals Inc (+$7.07M), AZN (+$7.01M).
- Started 28 new stock positions in CNC, Taro Pharmaceutical Industries, Liquidia Technologies Inc, Sarepta Therapeutics, Inflarx Nv, Aquestive Therapeutics Inc, SPECTRUM PHARMACEUTICALS INC Cmn Stock cmn, Guardant Health Inc, Tg Therapeutics, Bristol Myers Squibb Co right 12/30/2030.
- Reduced shares in these 10 stocks: AMRN (-$8.88M), Zogenix (-$7.72M), , DXCM (-$7.11M), ABMD (-$5.33M), Ascendis Pharma A S, R1 Rcm, ILMN, , BDSI.
- Sold out of its positions in ABMD, Aimmune Therapeutics Inc call, Aimmune Therapeutics Inc put, ALNY, ARQL, Cel-sci Corp, Celgene Corp right 12/31/2011, Codexis Inc, IVC, Newlink Genetics Corporation. Savara, Tricida Inc.
- Eversept Partners was a net buyer of stock by $133.44M.
- Eversept Partners has $516.25M in assets under management (AUM), growing by 61.17%.
Portfolio Holdings for Eversept Partners
Companies in the Eversept Partners portfolio as of the December 2019 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Share Count | Change in Shares | Price |
|---|---|---|---|---|
| GlaxoSmithKline (GSK) | 9.41 | 1.02M | +4% | 47.48 |
| Ensign (ENSG) | 5.95 | 676058 | +15% | 45.42 |
| Danaher Corporation (DHR) | 5.87 | 197107 | +10% | 153.63 |
| Ascendis Pharma A S | 5.47 | 202894 | -14% | 139.12 |
| Zogenix | 5.00 | 495645 | -23% | 52.13 |
| Sanofi-Aventis SA (SNY) | 4.29 | 441661 | +84% | 50.20 |
| Chemocentryx | 3.93 | 513189 | NEW | 39.55 |
| Amarin Corporation (AMRN) | 3.80 | 915590 | -31% | 21.44 |
| Audentes Therapeutics Inc Com stock | 3.54 | 305726 | +20% | 59.84 |
| BioCryst Pharmaceuticals (BCRX) | 3.28 | 4.90M | +649% | 3.45 |
| Vertex Pharmaceuticals Incorporated (VRTX) | 3.10 | 73009 | +43% | 218.95 |
| Envista Hldgs Corp | 2.91 | 506678 | +59% | 29.64 |
| Amarin Corp Plc option | 2.68 | 9942 | +517% | 1390.87 |
| Pennant Group Inc | 2.38 | 371193 | NEW | 33.07 |
| Medicines Company (MDCO) | 1.88 | 114358 | NEW | 84.94 |
| Sarepta Therapeutics | 1.87 | 75000 | NEW | 129.04 |
| Spdr S&p 500 Etf Tr option | 1.84 | 1600 | NEW | 5931.25 |
| Apellis Pharmaceuticals Inc | 1.84 | 310409 | +290% | 30.62 |
| Tg Therapeutics | 1.67 | 776323 | 11.10 | |
| Deciphera Pharmaceuticals Inc | 1.55 | 128748 | +485% | 62.24 |
| Model N | 1.41 | 207615 | +72% | 35.07 |
| Fate Therapeutics | 1.37 | 360656 | +156% | 19.57 |
| AstraZeneca (AZN) | 1.36 | 140562 | NEW | 49.86 |
| Bluebird Bio | 1.25 | 73400 | NEW | 87.75 |
| Radius Health | 1.24 | 318811 | -7% | 20.16 |
| Argenx Se | 1.16 | 37204 | +3% | 160.52 |
| Illumina (ILMN) | 1.14 | 17750 | -33% | 331.72 |
| Oxford Immunotec Global | 1.12 | 349823 | +36% | 16.60 |
| R1 Rcm | 1.05 | 416726 | -42% | 12.98 |
| Natera | 1.03 | 157081 | NEW | 33.69 |
| Kadmon Hldgs Inc Com stock | 1.00 | 1.14M | NEW | 4.53 |
| Guardant Health Inc | 0.98 | 64720 | NEW | 78.14 |
| Qiagen Nv | 0.90 | 137000 | NEW | 33.80 |
| eHealth (EHTH) | 0.59 | 31653 | -25% | 96.07 |
| Omega Healthcare Investors (OHI) | 0.59 | 71500 | -32% | 42.35 |
| Anthem | 0.58 | 10000 | NEW | 302.00 |
| Agile Therapeutics | 0.55 | 1.14M | +24% | 2.50 |
| Xenon Pharmaceuticals | 0.55 | 215609 | 13.11 | |
| LTC Properties (LTC) | 0.51 | 59327 | -14% | 44.77 |
| Dex (DXCM) | 0.51 | 12050 | -72% | 218.76 |
| Centene Corporation (CNC) | 0.49 | 40000 | NEW | 62.88 |
| Igm Biosciences Inc Com | 0.48 | 64600 | NEW | 38.16 |
| Affimed Therapeutics B V | 0.46 | 857771 | +166% | 2.74 |
| Collegium Pharmaceutical Inc Common Stock Usd | 0.44 | 111361 | -30% | 20.58 |
| Caretrust Reit | 0.43 | 107464 | -21% | 20.84 |
| BioDelivery Sciences International (BDSI) | 0.41 | 335485 | -52% | 6.32 |
| Otonomy | 0.41 | 550665 | +46% | 3.83 |
| Heska Corporation (HSKAD) | 0.39 | 20771 | -49% | 95.95 |
| Aquestive Therapeutics Inc | 0.39 | 350000 | NEW | 5.82 |
| Albireo Pharma | 0.38 | 78029 | +332% | 25.41 |
| Cytokinetics | 0.37 | 181700 | 10.61 | |
| Teligent | 0.37 | 4.50M | 0.43 | |
| Humana (HUM) | 0.36 | 5009 | NEW | 366.74 |
| Community Health Systems (CYH) | 0.33 | 580364 | -4% | 2.90 |
| Scpharmaceuticals Inc | 0.33 | 301636 | +36% | 5.66 |
| Sabra Health Care REIT (SBRA) | 0.31 | 76054 | -50% | 21.34 |
| Myokardia | 0.30 | 21452 | NEW | 72.91 |
| Inflarx Nv | 0.26 | 334618 | NEW | 3.96 |
| Sesen Bio Inc | 0.26 | 1.30M | NEW | 1.04 |
| Macrogenics | 0.25 | 116998 | -24% | 10.88 |
| Liquidia Technologies Inc | 0.24 | 284103 | NEW | 4.28 |
| Immunovant Inc | 0.24 | 76866 | NEW | 15.87 |
| Eiger Biopharmaceuticals | 0.20 | 69708 | 14.91 | |
| Optinose Inc | 0.19 | 105006 | 9.22 | |
| SPECTRUM PHARMACEUTICALS INC Cmn Stock cmn | 0.14 | 2756 | NEW | 252.90 |
| Pfenex | 0.10 | 46293 | -3% | 10.97 |
| Forty Seven Inc | 0.09 | 11795 | NEW | 39.34 |
| Taro Pharmaceutical Industries | 0.08 | 4953 | NEW | 88.03 |
| Dicerna Pharmaceuticals | 0.08 | 18674 | -54% | 22.01 |
| Tg Therapeutics | 0.04 | 415 | NEW | 551.81 |
| Intuitive Surgical (ISRG) | 0.01 | 131 | NEW | 587.79 |
| Akorn (AKRX) | 0.01 | 40242 | 1.49 | |
| Healthequity | 0.01 | 400 | -37% | 75.00 |
| Radius Health Inc cmn | 0.00 | 56 | NEW | 89.29 |
| Bristol Myers Squibb Co right 12/30/2030 | 0.00 | 6000 | NEW | 0.50 |
Download CSV 
Past Filings by Eversept Partners
View past SEC 13F filings by Eversept Partners
- Eversept Partners 2019 Q3 filed Nov. 13, 2019
- Eversept Partners 2019 Q2 amended filed Oct. 30, 2019
- Eversept Partners 2019 Q2 filed Aug. 13, 2019
- Eversept Partners 2019 Q1 filed May 14, 2019
- Eversept Partners 2018 Q4 filed Feb. 13, 2019
- Eversept Partners 2018 Q3 filed Nov. 14, 2018
- Eversept Partners 2018 Q2 filed Aug. 14, 2018
- Eversept Partners 2018 Q1 filed May 14, 2018
- Eversept Partners 2017 Q4 amended filed Feb. 13, 2018
- Eversept Partners 2017 Q4 filed Feb. 12, 2018